Market Research Report
Biosimilars Market Access in the EU
|Published by||Datamonitor Healthcare||Product code||604015|
|Published||Content info||137 Pages
Delivery time: 1-2 business days
|Biosimilars Market Access in the EU|
|Published: January 19, 2018||Content info: 137 Pages||
Biosimilars have been available in Europe for over a decade, and have offered the opportunity to vastly reduce the cost of treatment for a large number of biologic agents. In order to deliver significant savings to the healthcare structure of each individual EU member state, a careful inspection of the market access, pricing, and reimbursement mechanisms in force in each region is paramount. An in-depth knowledge of what drives payer and physician decision-making on biosimilar use is crucial for biosimilar developers wishing to design market access strategies uniquely tailored to the specific demands in each EU member state.
This analysis summarizes key information on the process of biosimilar approval in Europe, along with associated challenges, and provides highlights on country-specific market access, pricing, and reimbursement mechanisms which drive biosimilar uptake or prove a barrier to their entrance.